Press Releases

Date Title and Summary    
Toggle Summary Rexahn Announces Adjournment of Annual Meeting of Shareholders until Wednesday, June 27, 2018
Three of four proposals pass with shareholder approval Annual Meeting adjourned solely with respect to Proposal 3 — approval of an amendment to the Company's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock ROCKVILLE, Md., June 14, 2018
View HTML Print
Toggle Summary Rexahn Pharmaceuticals Announces Presentations at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting
Phase 2a Trial of RX-5902 Advances to Stage 2 Based on Encouraging Progression Free Survival and Evidence of Tumor Shrinkage Observed in Heavily Pre-treated Metastatic Triple Negative Breast Cancer Patients Phase 2a Trial of RX-3117 Demonstrates Encouraging Efficacy, Including a Complete Response,
View HTML Print
Toggle Summary Rexahn Phase 2a Combination Study of RX-3117 and Abraxane® in First-line Metastatic Pancreatic Cancer Patients Advances to Second Stage
Routine Safety Monitoring Committee Review Confirmed No Dose Reductions Necessary
View HTML Print
Toggle Summary Rexahn Reports First Quarter 2018 Financial Results
ROCKVILLE, Md., May 07, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, announced financial results for the first quarter ended March 31, 2018.
View HTML Print
Toggle Summary Rexahn to Present Clinical Data at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Preliminary Safety and Efficacy Data from Phase 1b/2a Trial of RX-5902 in Advanced Triple Negative Breast Cancer Updated Safety and Efficacy Data on RX-3117 in Advanced Urothelial (Bladder) Cancer ROCKVILLE, Md., April 26, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc.
View HTML Print
Toggle Summary Rexahn Pharmaceuticals to Present at Two Upcoming Conferences
B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium (CHIPS) on March 16 Oppenheimer 28th Annual Healthcare Conference on March 21 ROCKVILLE, Md., March 13, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company
View HTML Print
Toggle Summary Rexahn Pharmaceuticals Reports Full Year 2017 Financial Results
ROCKVILLE, Md., March 12, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced financial results for the year ended December 31, 2017.
View HTML Print
Toggle Summary Rexahn Reports Data from the Ongoing Phase 2a Clinical Trial of RX-3117 in Advanced Bladder Cancer at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) 2018 Annual Meeting
Encouraging Progression Free Survival and Evidence of Tumor Shrinkage Observed in Patients with Advanced Bladder Cancer Who Had Failed on Multiple Prior Treatments Including Immunotherapy and Gemcitabine
View HTML Print
Toggle Summary Rexahn Pharmaceuticals Announces Collaboration with Zhejiang Haichang Biotechnology Co., Ltd. for the Development of RX-0201 (Archexin®) for the treatment of Hepatocellular Carcinoma
Haichang to fund development through completion of Phase IIa Proof-of-Concept Clinical Trial Clinical trials will be designed to meet both the US and China FDA requirements ROCKVILLE, Md., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc.
View HTML Print
Toggle Summary Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) 2018 Annual Meeting
ROCKVILLE, Md., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that it will present preliminary clinical data from the Phase 2a
View HTML Print


©2018 by Rexahn Pharmaceuticals, Inc. All rights reserved
Rexahn Pharmaceuticals, Inc. - 15245 Shady Grove Road, Suite 455 - Rockville, MD 20850

Terms of Use
Privacy Policy